· The global market for facial injectables is anticipated to be worth USD 21.57 billion by 2027, expanding at a CAGR of 11.8% during this period, according to a recent report by Grand View Research.
· According to ASAPS, the United States saw more than USD 1 billion being spent on injectables in 2018 by the consumers, which points towards the fact the market is primed for appreciable growth in the coming years. The year also saw a high number of surgical and nonsurgical procedures performed, the number being 1,533,640 for the former and 3,315,888 for the latter.
· Nonsurgical procedures include injectables, facial rejuvenation, as well as other techniques that includes hair removal and sclerotherapy. Out of these, injectables were the segment with the highest demand by quite a distance, the methods including botulinum toxin (1,801,033 procedures), calcium hydroxylapatite (31,821 procedures), hyaluronic acid (810,240 procedures), and Poly-L-Lactic acid (28,036).
“Try a Free Sample Report” Click the link below:
· When compared with the number of nonsurgical procedures performed in 2017, the injectables segment witnessed a healthy rise of 13.9%, and this growth became 38.7% when compared with the data from 2014. Additionally, among the methods used, only botulinum toxin and hyaluronic acid have shown growth over the previous years, while the others have seen a sharp decline.
· The gender demographic for facial injectable procedures sharply skews towards females, with the 92.3% of the total number of injectable procedures in 2018 being performed on women, while men constituted a measly 7.7% in this area. Of this, hyaluronic acid and poly-l-lactic acid procedures showed the biggest gap, with 95.1% and 96.5% respectively being undertaken on women.
· According to the CIA World Fact Book, with respect to nation-wise age demographic, Germany has 38.58% of its population in the age group of 25–54 years, while the age group of 55–64 years constitutes 15.74% of the population. The population in terms of gender is almost equally divided in these age groups, which translates to huge market opportunities for facial injectables in this region.
· The global hyaluronic acid market is anticipated to be worth USD 16.6 billion by the year 2027, according to a Grand View Research report, with the growing adoption of aesthetic procedures in different developed and developing regions, which will directly have a positive impact on the facial injectables market.
· In terms of product, the facial injectables market has been segmented into collagen, botulinum toxin Type A, calcium hydroxylapatite, hyaluronic acid and polymer fillers. The hyaluronic acid segment dominated the market in 2019, owing to its increasing application in cosmetics industry on account of its strong water retention properties and negligible allergic reactions. Another segment which is expected to witness appreciable growth in the coming years is botulinum toxin type A, on account of its utility in cosmetics industry, as well as therapeutic applications.
· Region-wise, North America accounted for more than 40% share of the facial injectables market in 2019, aided by the presence of a large ageing population, coupled with the easy availability of products. the US is expected to remain an attractive market for the product, with the United States Census Bureau projecting the geriatric population to rise to almost 84 million by 2050, which would increase demand for cosmetics procedures. Europe also contributes to a substantial market revenue, on account of the presence of a number of market players in the region.
“Try a Free Sample Report” Click the link below:
Recent Trends and Developments
· The International Association for Physicians in Aesthetic Medicine (IAPAM) has identified a few trends that have emerged in the aesthetic space in the past two years, which are expected to have a major say in the facial injectables market in the coming years. These include facial contouring, adding volume and definition to the face to create a youthful appearance, platelet rich plasma (PRP), non-surgical rhinoplasty, laser resurfacing facial treatment, and lip injections/fillers.
· Allergan received the FDA approval for its HA gel dermal filler, the Juvéderm® VOLUMA XC, with a TSK STERiGLIDE™ cannula for the purpose of cheek augmentation, in May 2019. This is the first approval for cannula that the company has received for their Juvéderm filler collection.
· In April 2019, Merz launched the Belotero® Revive, a dermal filler that has been designed to improve elasticity, hydration and firmness of the skin, while addressing the appearance of fine lines. The product contains a combination of hyaluronic acid (HA) and glycerol. The product was made available at launch in select European and Latin American countries, while additional markets were added in the later part of 2019.
· Galderma presented new research across their neurotoxin and dermal filler portfolio at the 2019 American Society for Dermatologic Surgery Annual Meeting in Chicago in October, which highlighted the Phase 3 results for an innovative lip augmentation treatment, and certain findings on the measurement of dermal filler flexibility.
“Try a Free Sample Report” Click the link below:
